Sugimachi K, Miyauchi Y, Inutsuka S, Kakegawa T, Nishi M, Tomita M, Koga Y, Ishigami K, Inokuchi K
Gan No Rinsho. 1987 Jun;33(7):777-83.
The effectiveness of surgical adjuvant immunochemotherapy was studied on 287 patients with thoracic esophageal cancer in the Kyushu and Yamaguchi districts. Pre- and postoperative subcutaneous administrations of BCG, 10 mg once a week and an oral administration of PSK, 3 g a day, for as long as possible after surgery were instituted. The control group was designated as the one which neither PSK nor BCG was given. Most patients received chemotherapy and/or radiotherapy. Significant elongation of survival time was observed in immunotherapy patients with stage III and in those with non-curative resection, both having no lymph node metastasis.
在九州和山口地区,对287例胸段食管癌患者进行了手术辅助免疫化疗疗效的研究。术后尽可能长时间进行卡介苗(BCG)皮下注射,每周10mg,术前术后各一次,同时口服云芝多糖(PSK),每天3g。对照组为既未给予PSK也未给予BCG的患者。大多数患者接受了化疗和/或放疗。在III期免疫治疗患者以及非根治性切除且无淋巴结转移的患者中,观察到生存时间显著延长。